OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7

THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS

OCTOBER 27 - 28, 2017HILTON HABTOOR HOTEL, LEBANON

THE 2ND CONTINUOUSEDUCATION FOR

7

ONCOLOGYPRACTITIONERS

3 CE CREDITS

THE LEBANESE ORDEROF PHARMACISTS

IN COLLABORATION WITH:

OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7

THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS

OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7

THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS

Friday October 27, 2017

13:00 Registration

14:00 - 14:15 Welcoming Note and Introduction Fadi Nasr

14:15 - 14:35 Cancer Patient Support Hani Nassar14:15 - 14:20 BNA Main Achievements: Facts & Figures14:20 - 14:30 Patients Testimonials14:30 - 14:35 Future Projects

14:35 - 15:35 CLLModerators: Souad Maalouf - Daisy Samaha - Tony Yammine - Perla Mousallem

14:35 - 14:55 Chemotherapy Free Era in CLLLecture Sponsored by Abbvie

Colette Hanna

14:55 - 15:05 Nurse Perspective Sahar Attieh15:05 - 15:15 Clinical Pharmacy Perspective Nadine Zaineb15:15 - 15:25 Cytogenetic Perspective Alain Chebly15:25 - 15:35 Internal Medicine Souhail Araa

15:35 - 16:00 Coffee Break

16:00 - 16:30Moderators: Rabih Tamim - Manale DibExploring New Directions in NSCLCSymposium Sponsored by Roche

Fadi El Karak

16:30 - 17:30 Multiple Myeloma

Moderators: Elie Rassy - Warde Semaan - Hala Sacre - Jean Claude KhairallahHadi Ghanem - Arlette Hajjar

16:30 - 16:40 Case Presentation Ahmad Khalil16:40 - 16:50 Nurse Perspective Paula Zoghby16:50 - 17:00 Clinical Pharmacy Perspective Aline Hajj17:00 - 17:10 Cytogenetic Perspective Rima Korban17:10 - 17:20 Rheumatology Perspective Jeanine Mnassa17:20 - 17:30 Oncology Perspective Fadi Nasr

THE LEBANESE ORDEROF PHARMACISTS

1 C.E. Credit

OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7

THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS

OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7

THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS

Saturday October 28, 201708:00 Registration09:00 - 10:00 Breast Cancer

Moderators: Marcel Massoud - Leony Antoun - Pierre Najem - Lamis Araa09:00 - 09:12 Case Presentation Anthony Tarabay09:12 - 09:24 Nurse Perspective Stephanie Kaddoum09:24 - 09:36 Clinical Pharmacy Perspective Aline Saad09:36 - 09:48 Surgeon Perspective Michel Hokayem09:48 - 10:00 Oncology Perspective Marcel Massoud

Moderators: Rita Rizk - Joya Dagher10:00 - 10:30 Kisqali (Ribociclib): Power That Redefines First Line

Symposium Sponsored by NovartisDiscussion: Latife Karam Kirejian

Fadi Nasr

10:30 - 11:00 Coffee Break

Moderators: Zeina Hachem - Janah Madah11:00 - 11:40 The Road Ahead in the Management of HR+ mBC

Patients: Are There Differences Between CDK4/6 Inhibitors?Symposium Sponsored by Pfizer

Georges ChahineFadi Nasr

11:40 - 12:00 Psychology of CancerModerator: Rita Sakr

11:40 - 12:00 Evidence & Methods for Supporting Cancer Patients Toni Sawma

12:00 - 12:15 Advanced Nursing PracticeModerator: Gisele Hajal

12:00 - 12:15 Advanced Nursing Practice in Oncology Rima Sassine Kazan

Moderators: Georges Maalouly - Lynn Abdo12:15 - 13:15 Immunotherapy: Redefining Cancer Treatment:

Pembrolizumab in NSCLC, UC, cHLFadi Nasr

Symposium Sponsored by MSDDiscussion: Randa Choueiri

THE LEBANESE ORDEROF PHARMACISTS

2 C.E. Credits

OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7

THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS

Saturday October 28, 2017

Moderator: Nadine Bou Micheal - Noha Al Hachem13:15 - 13:35 Optimizing Treatment Outcomes in Metastatic Gastric

CancerSymposium Sponsored by Eli Lilly

Marwan Ghosn

13:35 - 14:35 Lunch Break

14:35 - 15:35 Lung CancerModerators: Georges Chahine - May Fakhoury - Rachel Ferekh

14:35 - 14:45 Case Presentation Roland Eid14:45 - 14:55 Nurse Perspective Noura Merhi14:55 - 15:05 Clinical Pharmacy Perspective Hanine Elias15:05 - 15:15 Pulmonary Perspective Ihab Ibrahim15:15 - 15:35 New Treatment in Lung Cancer Georges Chahine

Moderator: Carole Deeb15:35 - 16:05 Biosimilars: Pharmaceutical and Clinical Considerations

Symposium Sponsored by RocheFadi Farhat

16:05 - 16:30 Coffee Break

16:30 - 17:10 Current and Evolving Treatment Landscape for I-O in Head and Neck CancersSymposium Sponsored by BMS

Fadi Nasr

Round Table: Georges Farha - Caroline Jabbour - Tanios Eid - Fares Azouri Clement Khoury - Sami Melki - Rami Saade - Antoine Melkane - Charbel Rameh

17:10 - 18:10 Colorectal CancerModerators: Fadi Nasr - Jinane Razzouk - Yasmine Yared - Joseph Amara

17:10 - 17:20 Case Presentation Evelyne Helou17:20 - 17:30 Nurse Perspective Bernard Badr17:30 - 17:40 Clinical Pharmacy Perspective Carole Deeb17:40 - 17:50 Gastroenterology Perspective Antoine Abi Abboud17:50 - 18:10 New Treatment in Colorectal Cancer Evelyne Helou

THE LEBANESE ORDEROF PHARMACISTS

2 C.E. Credits

OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7

THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS

Notes

Non Small Cell Lung Cancer FIRST-LINE as a s ingle agent for the treatment of p atients with metastatic NSCLC whose tumors have high P D-

L1 expression TPS ≥50%.

FIRST-LINE in combination with pemetrexed and carboplatin, for the treatment of patients with metastatic nonsquamous NSCLC.

SECOND-LINE as a s ingle agent for the treatment of patients with metastatic N SCLC whose tumors express PD- L1 (TPS ≥1%) w ith disease progression o n o r a fter platinum-containing chemotherapy.

Urothelial Carcinoma FIRST-LINE for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not

eligible for cisplatin-containing chemotherapy.

SECOND-LINE for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant

or adjuvant treatment with platinum-containing chemotherapy

Classical Hodgkin Lymphoma For the treatment of adult and pediatric patients with refractory cHL, or who have relapsed after 3 or more prior

lines of therapy

Melanoma FIRST & SECOND-LINE for the treatment of patients with unresectable or metastatic melanoma

Head and Neck Squamous Cell Cancer For the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-

containing chemotherapy.

MSD ONCOLOGY Lebanon : Azar Bldg. 2nd Floor Beirut, Tel: +961 1 483300 Fax: +961 1 493300 Full prescribing information is available upon request. For further inquiries please email at:DPOC_le vant@merck.com OCT-2018-LEB-ONCO-1235645-0000

DPOC_le vant@m er ck. com OCT-2018-LEB-ONCO-1235645-0000

Reference: Keytruda Lebanon Summary of Product Characteristics July 2017 TPS: Tumor Proportion Score PD-L: Programmed death Ligand

CEOP 2017 would like to thank the below sponsorsfor their contribution to the success of its annual congress

4th FLOOR, QUBIC CENTER, DAOUD AMMOUN STREET, HORSH TABET - SIN EL FILP.O BOX: 90-361 BEIRUT, LEBANON | TEL: +961 1 510880/1/2/3 | FAX Ext. 121EMAIL: INFOMED@INFOMEDWEB.COM | WEB: WWW.INFOMEDWEB.COM

Organised by: